So, in my opinion, the usage of PegIFN+LDT in a trial (controlled environment) is safe and can bring many benefits, as the
action of LDT is a good one. I read a lot
of good reports for LDT
action and the only bad one was related to some possible resistance, but it seams that this can be avoided in future if the sequencing will be used.
maybe next step is a combo, but a personalized combo (base on sequenceing, hbsag, hbeag, alt, ast, fibroscan, age, ... other ...